M-CENK
Phase 2Small molecule
M-CENK is one of 76 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Nizoral
WWim Janssens
Phase 3
Tecentriq
RochePhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
M-CENK
IImmunityBio, Inc.
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer1 trial
Platinum-resistant Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for M-CENK. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmunityBio, Inc.